Owlet Announces UK Medical Certification of Dream Sock®
Parents in the United Kingdom will soon have access to Owlet’s Dream Sock with UKCA certificationLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”...
Epidemics
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an...
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4...
Owlet Announces European Medical Certification of Dream SockⓇ
Parents will soon have access to Owlet’s Dream Sock with medically-certified CE-Marking across the European marketsLEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet”...
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in...
HCA Healthcare Reports First Quarter 2024 Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31,...
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of...
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseasesMOUNTAIN VIEW, Calif.,...
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its...
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral...
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing...
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents...
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey...
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing...
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded...
HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance
Bill Rutherford to Retire and Mike Marks to Become CFONASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and...
